While it has been postulated that Treg from patients with secondary mutations restoring CD18 function in some cells (reversion mutations) display reduced suppressive activity and may contribute to the development of intestinal bowel disease (IBD) in these patients (14), their direct contribution to the induction of autoimmunity remains unclear. This evidence concerns the gene ITGB2 and inflammatory bowel disease.